Technical Analysis for XLO - Xilio Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 2.75% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.75% | |
| Inside Day | Range Contraction | 2.75% | |
| Wide Bands | Range Expansion | 2.75% | |
| Down 3 Days in a Row | Weakness | 2.75% | |
| Gapped Down | Weakness | 2.75% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 22 hours ago |
| Rose Above 20 DMA | about 22 hours ago |
| Non-ADX 1,2,3,4 Pullback Entry | about 22 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Up 5% | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.25 |
| 52 Week Low | 0.49 |
| Average Volume | 1,466,661 |
| 200-Day Moving Average | 1.42 |
| 50-Day Moving Average | 1.04 |
| 20-Day Moving Average | 1.13 |
| 10-Day Moving Average | 1.17 |
| Average True Range | 0.13 |
| RSI (14) | 49.49 |
| ADX | 22.07 |
| +DI | 19.62 |
| -DI | 19.78 |
| Chandelier Exit (Long, 3 ATRs) | 0.99 |
| Chandelier Exit (Short, 3 ATRs) | 1.35 |
| Upper Bollinger Bands | 1.30 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | 0.47 |
| BandWidth | 29.34 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.012 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.21 | ||||
| Resistance 3 (R3) | 1.21 | 1.18 | 1.20 | ||
| Resistance 2 (R2) | 1.18 | 1.16 | 1.18 | 1.19 | |
| Resistance 1 (R1) | 1.15 | 1.14 | 1.17 | 1.15 | 1.18 |
| Pivot Point | 1.12 | 1.12 | 1.13 | 1.12 | 1.12 |
| Support 1 (S1) | 1.09 | 1.10 | 1.11 | 1.09 | 1.06 |
| Support 2 (S2) | 1.06 | 1.08 | 1.06 | 1.05 | |
| Support 3 (S3) | 1.03 | 1.06 | 1.05 | ||
| Support 4 (S4) | 1.03 |
